Table 1.
Medicare Part D Public Use File – Abiraterone and Enzalutamide
| 2013 | 2014 | 2015 | 2016 | Total | |
|---|---|---|---|---|---|
| Abiraterone | |||||
| Beneficiaries | 14,187 | 17,044 | 16,963 | 16,247 | - |
| Claims | 71,423 | 98,469 | 100,371 | 96,756 | 367,019 |
| Prescribers | 6,563 | 7,528 | 7,512 | 7,397 | - |
| Low users | 4,523 | 5,398 | 4,398 | 4,464 | - |
| Urologist – moderate | 95 | 278 | 301 | 289 | - |
| Urologist - high | 3 | 11 | 11 | 12 | - |
| Non-urologist – moderate | 1,925 | 2,536 | 2,669 | 2,490 | - |
| Non-urologist – high | 107 | 138 | 133 | 142 | - |
| Cost | $469,537,430 | $707,097,865 | $790,008,643 | $823,026,651 | $2,789,670,589 |
| Cost/beneficiary | $33,096 | $41,487 | $46,572 | $50,657 | - |
| Cost/claim | $6,574 | $7,181 | $7,871 | $8,506 | - |
| Claims/beneficiary | 5 | 5.8 | 5.9 | 6 | - |
| Enzalutamide | |||||
| Beneficiaries | 7,326 | 11,800 | 16,911 | 17,789 | - |
| Claims | 29,572 | 53,980 | 90,112 | 100,980 | 274,644 |
| Prescribers | 3,879 | 5,582 | 7,495 | 7,977 | - |
| Low users | 3,071 | 4,774 | 4,780 | 4,940 | - |
| Urologist – moderate | 21 | 82 | 464 | 651 | - |
| Urologist - high | 1 | 5 | 16 | 20 | - |
| Non-urologist – moderate | 742 | 1,371 | 2,102 | 2,228 | - |
| Non-urologist – high | 44 | 94 | 133 | 138 | - |
| Cost | $231,402,020 | $447,311,084 | $790,628,577 | $907,560,035 | $2,376,901,716 |
| Cost/beneficiary | $31,586 | $37,908 | $46,752 | $51,018 | - |
| Cost/claim | $7,825 | $8,287 | $8,774 | $8,988 | - |
| Claims/beneficiary | 4 | 4.6 | 5.3 | 5.7 | - |
Moderate prescribers prescribed > 10 prescriptions in a year for abiraterone or enzalutamide but to 10 or fewer beneficiaries total. High prescribers prescribed abiraterone or enzalutamide to greater than 10 beneficiaries total in the year. The Total column only includes totals for the number of claims and cost since number of prescribers and beneficiaries can overlap year to year.